HUP9901155A3
(en)
|
1996-02-13 |
2003-04-28 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
KR100446363B1
(ko)
|
1997-11-11 |
2004-09-01 |
화이자 프로덕츠 인코포레이티드 |
항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
TR200003719T2
(tr)
|
1998-06-19 |
2001-03-21 |
Pfizer Products Inc. |
Pirolo[2,3-d]Pirimidin bileşikleri
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
DK1117659T3
(da)
*
|
1998-09-29 |
2004-03-22 |
Wyeth Corp |
Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
AU6159499A
(en)
|
1998-09-29 |
2000-04-17 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
DE60037020T2
(de)
|
1999-07-09 |
2008-08-21 |
Glaxo Group Ltd., Greenford |
Anilinochinazoline als protein-tyrosin-kinasehemmer
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
CN100376567C
(zh)
|
1999-11-05 |
2008-03-26 |
阿斯特拉曾尼卡有限公司 |
作为vegf抑制剂的喹唑啉衍生物
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
PL218519B1
(pl)
|
1999-12-10 |
2014-12-31 |
Pfizer Prod Inc |
Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
|
AR029423A1
(es)
|
1999-12-21 |
2003-06-25 |
Sugen Inc |
Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
|
YU83302A
(sh)
|
2000-06-26 |
2005-09-19 |
Pfizer Products Inc. |
Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
|
CZ299561B6
(cs)
*
|
2000-06-30 |
2008-09-03 |
Glaxo Group Limited |
Chinazolinaminový derivát a farmaceutický prostredek
|
BR0112750A
(pt)
|
2000-07-26 |
2003-09-09 |
Smithkline Beecham Plc |
Aminopiperidina quinolinas e seus análogos azaisostéricos com atividade antibacteriana
|
IL154034A0
(en)
*
|
2000-08-09 |
2003-07-31 |
Astrazeneca Ab |
Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
ATE399766T1
(de)
|
2000-10-20 |
2008-07-15 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische heterozyklen
|
CN1854157B
(zh)
|
2001-01-05 |
2013-01-02 |
辉瑞大药厂 |
胰岛素样生长因子i受体的抗体
|
WO2002056912A2
(en)
*
|
2001-01-16 |
2002-07-25 |
Glaxo Group Limited |
Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
DE60212487T2
(de)
*
|
2001-04-13 |
2006-12-21 |
Pfizer Products Inc., Groton |
Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2003202263A1
(en)
|
2002-01-10 |
2003-07-30 |
Bayer Healthcare Ag |
Roh-kinase inhibitors
|
WO2003062209A2
(en)
*
|
2002-01-17 |
2003-07-31 |
Neurogen Corporation |
Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
|
WO2003062225A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
ATE381557T1
(de)
|
2002-01-23 |
2008-01-15 |
Bayer Pharmaceuticals Corp |
Rho-kinase inhibitoren
|
TW200406410A
(en)
|
2002-01-29 |
2004-05-01 |
Glaxo Group Ltd |
Compounds
|
AU2003239302A1
(en)
|
2002-01-29 |
2003-09-02 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
EP1483268A2
(de)
|
2002-03-01 |
2004-12-08 |
Pfizer Inc. |
Indolylurea-derivate von thienpyridinen zur verwendung als anti-angiogene mittel
|
EP1492568A1
(de)
*
|
2002-04-08 |
2005-01-05 |
SmithKline Beecham Corporation |
Verfahren zur behandlung von krebs durch verabreichung eines erb-gruppe-inhibitors und eines raf- und/oder ras-inhibitors
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
CA2491191C
(en)
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
US20050239784A1
(en)
*
|
2002-07-15 |
2005-10-27 |
Lacrampe Jean F A |
3-Phenyl analogs of toxoflavine as kinase inhibitors
|
CA2494061C
(en)
*
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
EP1551824B1
(de)
*
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein-tyrosine-kinase-inhibitoren
|
FR2846657B1
(fr)
*
|
2002-11-05 |
2004-12-24 |
Servier Lab |
Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
NZ540092A
(en)
|
2002-11-20 |
2007-06-29 |
Array Biopharma Inc |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
EP1572213A1
(de)
|
2002-11-26 |
2005-09-14 |
Pfizer Products Inc. |
Verfahren zur behandlung dertransplantatabstossung
|
AR042461A1
(es)
*
|
2002-12-13 |
2005-06-22 |
Neurogen Corp |
Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas
|
CA2510850A1
(en)
|
2002-12-19 |
2004-07-08 |
Pfizer Inc. |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
OA13309A
(en)
|
2002-12-20 |
2007-04-13 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth.
|
PT2476667E
(pt)
|
2003-02-26 |
2014-09-18 |
Sugen Inc |
Compostos de aminoheteroarilo como inibidores da proteína quinase
|
AU2004265226A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
US7008953B2
(en)
|
2003-07-30 |
2006-03-07 |
Agouron Pharmaceuticals, Inc. |
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
WO2005011607A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Smithkline Beecham Corporation |
Treatment of cancers expressing p95 erbb2
|
US20050038047A1
(en)
*
|
2003-08-14 |
2005-02-17 |
Edwards Paul John |
Azaquinazoline derivatives
|
JP2007504122A
(ja)
|
2003-08-29 |
2007-03-01 |
ファイザー・インク |
新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
|
AU2004270740A1
(en)
*
|
2003-09-09 |
2005-03-17 |
Neurogen Corporation |
4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
ES2925655T3
(es)
|
2003-09-26 |
2022-10-19 |
Exelixis Inc |
Moduladores c-Met y métodos de uso
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
GEP20084572B
(en)
|
2003-12-23 |
2008-12-25 |
Pfizer |
Novel quinoline derivatives
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
PT1746999E
(pt)
|
2004-05-06 |
2012-01-11 |
Warner Lambert Co |
4-fenilamino-quinazolin-6-il-amidas
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
AU2005251735A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
NZ552091A
(en)
|
2004-07-16 |
2009-09-25 |
Pfizer Prod Inc |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
CA2578066C
(en)
|
2004-08-26 |
2011-10-11 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
CA2583230A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
JP4881875B2
(ja)
|
2004-12-14 |
2012-02-22 |
アストラゼネカ アクチボラグ |
抗腫瘍剤としてのピラゾロピリミジン化合物
|
GB0428475D0
(en)
*
|
2004-12-30 |
2005-02-02 |
4 Aza Bioscience Nv |
Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
EP2444421A1
(de)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin-Antikörper
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
US8232278B2
(en)
*
|
2005-06-24 |
2012-07-31 |
Gilead Sciences, Inc. |
Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
|
EP1925676A4
(de)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Testverfahren für die wirkung eines vaskularisierungsinhibitors
|
JP5161777B2
(ja)
|
2005-09-07 |
2013-03-13 |
アムジェン フレモント インク. |
アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US7763731B2
(en)
*
|
2005-12-21 |
2010-07-27 |
Abbott Laboratories |
Anti-viral compounds
|
ATE541844T1
(de)
*
|
2005-12-21 |
2012-02-15 |
Abbott Lab |
Antivirale verbindungen
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
CN102633783A
(zh)
|
2006-02-10 |
2012-08-15 |
转化技术制药公司 |
作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
|
US20090036429A1
(en)
*
|
2006-02-17 |
2009-02-05 |
Ohler Norman E |
Hydroxypiperidine Derivatives and Uses Thereof
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
EP2036557B1
(de)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumorales mittel gegen schilddrüsenkrebs
|
KR100760148B1
(ko)
|
2006-07-19 |
2007-09-18 |
주식회사 엘지생활건강 |
알파-리포산을 안정화시킨 화장료 조성물
|
US8338435B2
(en)
*
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
WO2008067119A2
(en)
*
|
2006-11-27 |
2008-06-05 |
Smithkline Beecham Corporation |
Novel compounds
|
WO2008133753A2
(en)
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
US8143394B2
(en)
*
|
2006-12-26 |
2012-03-27 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
TW200840584A
(en)
*
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
US8637531B2
(en)
*
|
2006-12-26 |
2014-01-28 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyridmidines useful for treating viral infections
|
CA2673683C
(en)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
RU2455994C2
(ru)
|
2007-04-16 |
2012-07-20 |
Хатчисон Медифарма Энтерпрайзис Лимитед |
Пиримидиновые производные
|
EA016679B1
(ru)
|
2007-04-18 |
2012-06-29 |
Пфайзер Продактс Инк. |
Сульфониламидные производные для лечения аномального роста клеток
|
EP2141994A4
(de)
*
|
2007-04-26 |
2011-05-18 |
Avalon Pharmaceuticals |
Mehrringverbindungen und ihre verwendungen
|
AU2008249745B2
(en)
*
|
2007-05-09 |
2012-01-12 |
Pfizer Inc. |
Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
|
ES2424745T3
(es)
|
2007-09-07 |
2013-10-08 |
Agensys, Inc. |
Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12
|
MY150054A
(en)
|
2007-10-29 |
2013-11-29 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CA2710039C
(en)
*
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8314107B2
(en)
*
|
2008-04-23 |
2012-11-20 |
Rigel Pharmaceuticals, Inc. |
Carboxamide compounds and methods for using the same
|
US7829574B2
(en)
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
WO2010002998A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
EP3023426A1
(de)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
|
EP2330909B1
(de)
*
|
2008-08-12 |
2013-09-18 |
GlaxoSmithKline LLC |
Chemische verbindungen
|
PT2384326E
(pt)
|
2008-08-20 |
2014-06-09 |
Zoetis Llc |
Compostos de pirrolo[2,3-d]pirimidina
|
TW201008933A
(en)
*
|
2008-08-29 |
2010-03-01 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine compounds
|
WO2010036928A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Takeda Pharmaceutical Company Limited |
Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
|
AR073680A1
(es)
*
|
2008-09-26 |
2010-11-24 |
Takeda Pharmaceutical |
Prevencion y tratamiento de cancer con la mutacion del gen ras. composicion farmaceutica. uso.
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
CN101735200B
(zh)
*
|
2008-11-17 |
2013-01-02 |
岑均达 |
喹唑啉类化合物
|
TWI447108B
(zh)
|
2009-01-16 |
2014-08-01 |
Exelixis Inc |
N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
|
EP2393814A1
(de)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinylverbindungen als axl-kinase-inhibitoren
|
EP2400985A2
(de)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
|
EP2400990A2
(de)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2408479A1
(de)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
CN102597776A
(zh)
|
2009-09-11 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌剂的可能性升高的患者的方法
|
EP2478114B1
(de)
|
2009-09-17 |
2014-12-17 |
F.Hoffmann-La Roche Ag |
Verfahren zur lung krebsdiagnostik
|
TR201802464T4
(tr)
|
2009-10-29 |
2018-03-21 |
Genosco |
Ki̇naz i̇nhi̇bi̇törleri̇
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
PL2534153T3
(pl)
|
2010-02-12 |
2017-08-31 |
Pfizer Inc. |
Sole i polimorfy 8-fluoro-2-{4-[(metyloamino}metylo]fenylo}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-onu
|
EP2542893A2
(de)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2552915B1
(de)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Verbindungen zur behandlung von hiv
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011159835A1
(en)
|
2010-06-16 |
2011-12-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
PL2975042T3
(pl)
*
|
2010-06-23 |
2019-07-31 |
Hanmi Science Co., Ltd. |
Nowe pochodne skondensowanych pirymidyn do hamowania aktywności kinaz tyrozynowych
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
CA2805709A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
ES2543151T3
(es)
|
2010-10-20 |
2015-08-17 |
Pfizer Inc |
Derivados de 2-piridina como moduladores del receptor Smoothened
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
WO2012145183A2
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
EP2702173A1
(de)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
MX2014002436A
(es)
|
2011-08-31 |
2014-05-27 |
Genentech Inc |
Marcadores de diagnostico.
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック, インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
EP2776467A1
(de)
|
2011-11-08 |
2014-09-17 |
Pfizer Inc |
Verfahren zur behandlung von entzündungserkrankungen mit anti-m-csf-antikörpern
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
EP2937337A4
(de)
|
2012-12-21 |
2016-06-22 |
Eisai R&D Man Co Ltd |
Amorphe form von chinolinderivaten und verfahren zur herstellung davon
|
EP2961412A4
(de)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
Krebstherapie
|
BR112015022993B1
(pt)
|
2013-03-14 |
2021-12-14 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes
|
WO2014151106A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
US20160051556A1
(en)
|
2013-03-21 |
2016-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
AR096654A1
(es)
|
2013-06-20 |
2016-01-27 |
Ab Science |
Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN111808957A
(zh)
|
2014-04-04 |
2020-10-23 |
中美冠科生物技术(太仓)有限公司 |
用于确定对mek/erk抑制剂的应答性的方法
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
MA49708A
(fr)
|
2014-04-30 |
2020-06-03 |
Pfizer |
Dérivés de dihétérocycle liés à cycloalkyle
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2925224T3
(es)
|
2014-07-31 |
2022-10-14 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
TWI721954B
(zh)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
高純度喹啉衍生物及其生產方法
|
EP3233829B1
(de)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidin und triazinderivate und deren verwendung als axl-inhibitoren
|
CN107223163A
(zh)
|
2014-12-24 |
2017-09-29 |
豪夫迈·罗氏有限公司 |
用于膀胱癌症的治疗,诊断和预后方法
|
RU2017128583A
(ru)
|
2015-02-25 |
2019-03-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Способ ослабления горечи хинолинового производного
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
CA2984421C
(en)
|
2015-05-01 |
2024-04-09 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
EP3298021B1
(de)
|
2015-05-18 |
2019-05-01 |
Tolero Pharmaceuticals, Inc. |
Alvocidib-prodrugs mit erhöhter bioverfügbarkeit
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
CA3006743A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
CN110234659A
(zh)
|
2016-12-19 |
2019-09-13 |
特雷罗药物股份有限公司 |
用于敏感性分析的分析肽和方法
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
AR112797A1
(es)
|
2017-09-08 |
2019-12-11 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP4268898A3
(de)
|
2018-06-11 |
2024-01-17 |
Amgen Inc. |
Kras-g12c-inhibitoren zur behandlung von krebs
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
EP3826684A4
(de)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Verfahren zur behandlung von mit abnormaler acvr1 -expression verbundenen krankheiten und acvr1 -inhibitoren zur verwendung in demselben
|
CA3113234A1
(en)
|
2018-09-18 |
2020-03-26 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
|
CN113194954A
(zh)
|
2018-10-04 |
2021-07-30 |
国家医疗保健研究所 |
用于治疗角皮病的egfr抑制剂
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
MX2021007158A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
WO2020132648A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
SG11202112855WA
(en)
|
2019-05-21 |
2021-12-30 |
Amgen Inc |
Solid state forms
|
JP2022542319A
(ja)
|
2019-08-02 |
2022-09-30 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4054719A1
(de)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
JP2022553857A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
EP4055017A1
(de)
|
2019-11-08 |
2022-09-14 |
Revolution Medicines, Inc. |
Bicyclische heteroarylverbindungen und verwendungen davon
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
CA3158188A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021257736A1
(en)
|
2020-06-18 |
2021-12-23 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
WO2022235864A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|